InvestorsHub Logo
Followers 53
Posts 1820
Boards Moderated 0
Alias Born 03/22/2015

Re: WeeZuhl post# 37853

Tuesday, 11/27/2018 8:31:59 AM

Tuesday, November 27, 2018 8:31:59 AM

Post# of 38634

Stay tuned for the next pump: Nasal/oral HAL study results will be described in a PR as a great success, but no data will be revealed to prove it is true.





Sorry, I was wrong. The next attempted pump will be an IND for oxy IR with PODRAS. Hmmmmmm. Didn't they receive Fast Track for oxy ER with PODRAS back in 2015? Yaaaaaaaaawwwwwwwwnnnnnnnnnnnn.


https://www.intellipharmaceutics.com/news-media/press-releases/detail/187/intellipharmaceutics-submits-investigational-new-drug

("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has submitted an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for its oxycodone hydrochloride immediate release ("IPCI006") tablets in the 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths.

Oxycodone hydrochloride is indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.

This novel drug formulation incorporates the Company's Paradoxical OverDose Resistance Activating System ("PODRAS™") delivery technology and its novel Point Of Divergence Drug Delivery System ("nPODDDS™") technology.







Call on God but row away from the rocks.

-Hunter S. Thompson

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPCI News